Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Where will Cipla share price be in the next 3 years? - livemint.com
Where will Cipla share price be in the next 3 years?livemint.com
Buy or sell: Gift Nifty rises, Vaishali Parekh recommends three stocks to buy today — 3 July 2026 - livemint.com
Buy or sell: Gift Nifty rises, Vaishali Parekh recommends three stocks to buy today — 3 July 2026livemint.com
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories continues to impress investors
Sun Pharma Share Price Live Updates: Sun Pharma achieves a notable 10.47% return in three months
Cipla Share Price Live Updates: Cipla's strong market performance
Blue Star Shares In Focus As PL Capital Initiates Coverage — Check Target Price
PL Capital initiates coverage on Blue Star with a bullish view given its strong earnings visibility, improving profitability and leadership across the HVAC industry.
Coal gasification pilot yet to take off despite ₹6,233 cr incentives
Nearly a year after awarding ₹6,233 crore for coal gasification projects, none have progressed beyond planning. Despite multiple task force meetings, ground work hasn't commenced, with commissioning now pushed to FY30. Meanwhile, a new ₹37,500 crore scheme has been launched, excluding first-round participants who now face disadvantages due to delays and lack of access to more generous incentives.
Red Bull, Campa, Monster and other beverage cos get notices over 'energy drink' claims
India's food regulator, FSSAI, has cracked down on major beverage brands like Red Bull and Monster, issuing notices for using the 'energy drink' label and making health-related claims. The authority states that no such category is recognized under current food safety laws. Companies are warned against promotional statements about boosting energy or focus, as these functional claims are not permitted for food products, aiming to prevent misleading branding.
Bank of Baroda to pay $600 million to settle NMC Health insolvency claims
Bank of Baroda has agreed to a $600 million settlement with administrators of the insolvent NMC Health Plc. The bank faced allegations of gross negligence, failing to conduct proper due diligence, and allowing fraudulent transactions without adhering to anti-money laundering and KYC norms. This payout, significantly exceeding its reported exposure, aims to resolve claims from NMC Health and its affiliates, stemming from a fraud discovered between 2012-2020.
Bank of Baroda to pay $600 million to settle NMC Health insolvency claims
Bank of Baroda has agreed to a $600 million settlement with administrators of the insolvent NMC Health Plc. The bank faced allegations of gross negligence, failing to conduct proper due diligence, and allowing fraudulent transactions without adhering to anti-money laundering and KYC norms. This payout, significantly exceeding its reported exposure, aims to resolve claims from NMC Health and its affiliates, stemming from a fraud discovered between 2012-2020.
Govt brings stem cell, gene therapies under central licensing framework
India's drug regulations have been updated to include advanced treatments like cell, stem cell, gene therapies, and xenografts under central licensing. This move aims to bolster oversight for these complex, evolving medical technologies, ensuring patient safety and uniform standards nationwide. The amendment signifies a commitment to public health while fostering innovation and faster adoption of cutting-edge healthcare solutions.
Market Trading Guide: Suven Life Sciences among 2 stock recommendations for Friday
Indian markets advanced on easing crude prices and dovish Fed commentary, boosting risk appetite. Analysts recommend buying NDR Auto and Suven Life Sciences after bullish breakouts, while investors await US jobs data, the India–Japan summit and Q1FY27 earnings.